Index RUT P/E 14.22 EPS (ttm) 0.18 Insider Own 28.31% Shs Outstand 47.65M Perf Week 2.77%
Market Cap 127.53M Forward P/E 13.22 EPS next Y 0.20 Insider Trans -1.33% Shs Float 35.16M Perf Month -3.70%
Income 8.72M PEG - EPS next Q 0.33 Inst Own 56.92% Short Float 9.89% Perf Quarter -13.04%
Sales 219.14M P/S 0.58 EPS this Y -42.22% Inst Trans -2.07% Short Ratio 7.33 Perf Half Y -51.40%
Book/sh 1.00 P/B 2.60 EPS next Y -24.36% ROA 4.30% Short Interest 3.48M Perf Year -10.34%
Cash/sh 1.97 P/C 1.32 EPS next 5Y - ROE 22.10% 52W Range 2.13 - 7.73 Perf YTD -39.95%
Dividend Est. - P/FCF 3.84 EPS past 5Y - ROI 9.03% 52W High -66.36% Beta 1.08
Dividend TTM - Quick Ratio 1.23 Sales past 5Y -0.59% Gross Margin 73.08% 52W Low 22.07% ATR (14) 0.18
Dividend Ex-Date - Current Ratio 1.32 EPS Y/Y TTM 439.42% Oper. Margin 8.91% RSI (14) 47.40 Volatility 5.35% 6.51%
Employees 185 Debt/Eq 2.03 Sales Y/Y TTM -4.77% Profit Margin 3.98% Recom 3.00 Target Price 4.33
Option/Short Yes / Yes LT Debt/Eq 0.99 EPS Q/Q -308.44% Payout 0.00% Rel Volume 1.26 Prev Close 2.56
Sales Surprise -0.67% EPS Surprise 30.77% Sales Q/Q -13.72% Earnings Aug 01 AMC Avg Volume 474.33K Price 2.60
SMA20 5.50% SMA50 -15.78% SMA200 -39.35% Trades
Volume 596,317 Change 1.56%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-28-21 Upgrade Citigroup
Neutral → Buy
$11
Jun-25-20 Resumed BofA/Merrill
Underperform
$9
Oct-08-19 Downgrade Goldman
Neutral → Sell
$24 → $8
May-10-19 Downgrade Citigroup
Buy → Neutral
$24
May-10-19 Downgrade Cantor Fitzgerald
Overweight → Neutral
$57 → $20
Jan-17-19 Initiated Leerink Partners
Mkt Perform
$21
Jan-03-19 Downgrade Guggenheim
Buy → Neutral
Nov-19-18 Upgrade Goldman
Sell → Neutral
Nov-02-18 Downgrade JP Morgan
Neutral → Underweight
Nov-02-18 Downgrade BofA/Merrill
Buy → Underperform
Oct-01-18 Initiated Cantor Fitzgerald
Overweight
$75
Sep-17-18 Initiated Goldman
Sell
$42
May-11-18 Reiterated Stifel
Buy
$95 → $87
Nov-10-17 Reiterated RBC Capital Mkts
Sector Perform
$92 → $108
Nov-10-17 Reiterated Citigroup
Buy
$156 → $164
Oct-02-17 Reiterated Stifel
Buy
$110 → $130
Sep-11-17 Reiterated Credit Suisse
Outperform
$118 → $136
Jul-10-17 Resumed Leerink Partners
Outperform
$115
Jun-06-17 Reiterated RBC Capital Mkts
Sector Perform
$60 → $88
May-25-17 Reiterated RBC Capital Mkts
Sector Perform
$40 → $60
Show Previous Ratings
Sep-12-24 07:59AM
Sep-03-24 04:15PM
Aug-21-24 05:00AM
Aug-06-24 05:23PM
(Business Wire) +12.26%
-7.44%
Aug-02-24 10:07AM
05:04PM
Loading…
Aug-01-24 05:04PM
(Associated Press Finance)
04:05PM
Jul-23-24 09:40AM
Jul-18-24 04:10PM
Jul-02-24 05:30PM
Jun-07-24 05:37PM
Jun-03-24 02:33PM
Jun-02-24 10:01AM
May-28-24 09:00AM
May-24-24 11:57AM
05:15PM
Loading…
May-23-24 05:15PM
May-20-24 09:59AM
May-03-24 01:09PM
11:31AM
04:02AM
May-02-24 09:55PM
06:05PM
05:48PM
05:12PM
(Associated Press Finance)
04:05PM
Apr-26-24 11:40AM
Apr-25-24 10:02AM
Apr-18-24 04:15PM
Apr-11-24 06:00PM
Apr-03-24 05:30PM
09:25AM
Loading…
Mar-22-24 09:25AM
Mar-20-24 08:30AM
Mar-02-24 08:29AM
Mar-01-24 09:55AM
(Thomson Reuters StreetEvents) -5.31%
09:40AM
09:39AM
Feb-29-24 04:41PM
04:40PM
(Associated Press Finance)
04:05PM
Feb-27-24 06:30PM
11:51AM
Feb-22-24 04:10PM
(Business Wire) -9.22%
+10.83%
Feb-15-24 04:10PM
Feb-13-24 08:30AM
Jan-31-24 12:58PM
Jan-11-24 04:07PM
Jan-06-24 11:02AM
Dec-11-23 08:30AM
Nov-20-23 11:47AM
Nov-06-23 05:15PM
Nov-03-23 12:16PM
09:34AM
(Thomson Reuters StreetEvents)
09:31AM
Nov-02-23 07:42PM
04:47PM
(Associated Press Finance)
04:05PM
Oct-19-23 04:14PM
Oct-14-23 12:30PM
Oct-04-23 05:30PM
Sep-22-23 07:57AM
Sep-21-23 04:10PM
Aug-31-23 04:07PM
Aug-08-23 08:30AM
Aug-04-23 12:36PM
09:23AM
(Thomson Reuters StreetEvents)
Aug-03-23 05:17PM
04:05PM
Jul-20-23 04:15PM
Jun-13-23 09:30AM
Jun-06-23 05:03PM
Jun-04-23 09:00AM
May-28-23 10:06AM
May-22-23 11:07AM
May-05-23 05:15PM
12:45PM
09:44AM
(Thomson Reuters StreetEvents)
May-04-23 05:32PM
04:04PM
Apr-20-23 04:15PM
Apr-17-23 06:49AM
Apr-11-23 05:15PM
Mar-14-23 08:30AM
Mar-06-23 09:48AM
Mar-03-23 05:15PM
02:20PM
06:22AM
(Thomson Reuters StreetEvents)
Mar-02-23 04:05PM
Feb-28-23 04:15PM
Feb-19-23 02:05PM
Feb-16-23 04:31PM
Feb-07-23 05:30PM
Feb-01-23 08:30AM
Jan-25-23 06:19AM
Jan-12-23 04:15PM
Jan-11-23 05:30PM
Jan-09-23 08:55AM
Dec-20-22 08:31AM
Dec-15-22 03:39PM
Dec-07-22 06:03PM
Dec-05-22 05:30PM
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MILLER MICHAEL PATRICK Director Aug 12 '24 Sale 3.49 23,358 81,466 47,000 Aug 13 09:09 PM MILLER MICHAEL PATRICK Director Aug 12 '24 Proposed Sale 3.76 23,358 87,826 Aug 12 09:27 PM NOUGUES MAXIMO F Chief Financial Officer Jul 17 '24 Sale 3.70 4,156 15,382 162,522 Jul 18 07:11 PM Ludwig Jeffrey Jerome Chief Commercial Officer Jul 17 '24 Sale 3.70 2,598 9,615 118,388 Jul 18 07:06 PM HUNT DOUGLAS M See Remarks Jul 17 '24 Sale 3.70 3,637 13,461 133,227 Jul 18 06:57 PM AUERBACH ALAN H President and CEO Jul 17 '24 Sale 3.70 21,920 81,128 7,063,515 Jul 18 06:50 PM NOUGUES MAXIMO F Chief Financial Officer Jul 02 '24 Sale 3.27 5,295 17,307 166,678 Jul 02 09:22 PM Ludwig Jeffrey Jerome Chief Commercial Officer Jul 02 '24 Sale 3.27 6,051 19,778 120,986 Jul 02 09:19 PM HUNT DOUGLAS M See Remarks Jul 02 '24 Sale 3.27 4,349 14,215 136,864 Jul 02 09:15 PM AUERBACH ALAN H President and CEO Jul 02 '24 Sale 3.27 18,885 61,726 7,085,435 Jul 02 09:10 PM WILSON TROY EDWARD Director Jun 13 '24 Sale 3.33 27,000 89,902 350 Jun 17 07:27 PM Stuglik Brian M Director Jun 13 '24 Sale 3.39 9,900 33,528 49,058 Jun 17 07:25 PM Senderowicz Adrian Director Jun 13 '24 Sale 3.33 27,000 89,818 0 Jun 17 07:23 PM MOYES JAY M Director Jun 13 '24 Sale 3.34 22,000 73,467 21,322 Jun 17 07:21 PM Dorval Allison Director Jun 13 '24 Sale 3.37 11,000 37,096 33,000 Jun 17 07:18 PM Wong Alvin F Chief Scientific Officer Dec 04 '23 Sale 3.76 280 1,053 97,934 Jan 10 04:41 PM Wong Alvin F Chief Scientific Officer Jan 03 '24 Sale 4.49 7,733 34,689 98,214 Jan 05 07:03 PM Ludwig Jeffrey Jerome Chief Commercial Officer Jan 03 '24 Sale 4.49 12,956 58,119 99,970 Jan 05 07:00 PM AUERBACH ALAN H President and CEO Jan 03 '24 Sale 4.49 41,396 185,698 6,936,947 Jan 05 06:56 PM NOUGUES MAXIMO F Chief Financial Officer Jan 03 '24 Sale 4.49 15,682 70,348 128,666 Jan 05 06:49 PM HUNT DOUGLAS M See Remarks Jan 03 '24 Sale 4.49 8,358 37,493 103,319 Jan 05 06:42 PM MILLER MICHAEL PATRICK Director Nov 07 '23 Sale 2.83 25,000 70,802 43,358 Nov 09 04:19 PM
Index RUT P/E - EPS (ttm) -2.60 Insider Own 26.18% Shs Outstand 81.97M Perf Week -5.64%
Market Cap 439.18M Forward P/E - EPS next Y -2.87 Insider Trans 0.34% Shs Float 62.47M Perf Month 1.37%
Income -192.65M PEG - EPS next Q -0.68 Inst Own 68.96% Short Float 26.14% Perf Quarter -1.89%
Sales 20.65M P/S 21.27 EPS this Y 17.45% Inst Trans 22.91% Short Ratio 11.20 Perf Half Y -60.71%
Book/sh 6.46 P/B 0.80 EPS next Y -11.55% ROA -29.87% Short Interest 16.33M Perf Year -59.48%
Cash/sh 6.81 P/C 0.76 EPS next 5Y - ROE -38.10% 52W Range 4.30 - 20.12 Perf YTD -62.77%
Dividend Est. - P/FCF - EPS past 5Y -67.06% ROI -31.67% 52W High -74.20% Beta 1.84
Dividend TTM - Quick Ratio 14.64 Sales past 5Y 126.44% Gross Margin 61.18% 52W Low 20.56% ATR (14) 0.47
Dividend Ex-Date - Current Ratio 14.64 EPS Y/Y TTM 18.15% Oper. Margin -1075.00% RSI (14) 42.56 Volatility 8.39% 8.93%
Employees 255 Debt/Eq 0.13 Sales Y/Y TTM 279.70% Profit Margin -933.02% Recom 1.20 Target Price 25.11
Option/Short Yes / Yes LT Debt/Eq 0.11 EPS Q/Q 32.14% Payout - Rel Volume 1.70 Prev Close 5.38
Sales Surprise 178.66% EPS Surprise 12.89% Sales Q/Q 219.73% Earnings Aug 08 BMO Avg Volume 1.46M Price 5.19
SMA20 -7.62% SMA50 -13.11% SMA200 -42.27% Trades
Volume 2,473,106 Change -3.53%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-08-24 Initiated H.C. Wainwright
Buy
$15
Apr-13-23 Initiated Canaccord Genuity
Buy
$29
Feb-01-23 Initiated Cantor Fitzgerald
Neutral
$21
Dec-15-22 Initiated Goldman
Sell
$13
Oct-06-22 Initiated Credit Suisse
Neutral
$48
Aug-25-22 Upgrade Stifel
Hold → Buy
$32 → $56
Jun-17-22 Initiated BMO Capital Markets
Outperform
$48
Feb-18-22 Initiated RBC Capital Mkts
Outperform
$42
Sep-24-21 Initiated Stifel
Hold
$58
Jul-12-21 Initiated William Blair
Outperform
$92
Jul-12-21 Initiated JP Morgan
Neutral
$50
Jul-12-21 Initiated Jefferies
Buy
$72
Jul-12-21 Initiated Guggenheim
Buy
$84
Show Previous Ratings
Today 04:40PM
Sep-12-24 01:15AM
Sep-08-24 04:51PM
11:49AM
Sep-05-24 08:30AM
04:05PM
Loading…
Sep-03-24 04:05PM
Aug-08-24 10:00AM
08:40AM
07:47AM
(Associated Press Finance)
07:00AM
Aug-02-24 04:05PM
(GlobeNewswire) -6.24%
-5.39%
Jul-08-24 07:07PM
(Insider Monkey) +8.00%
+10.76%
12:30PM
Jul-01-24 04:05PM
Jun-28-24 07:00AM
04:01PM
Loading…
May-31-24 04:01PM
07:00AM
May-30-24 04:01PM
May-17-24 06:27AM
May-12-24 04:00PM
May-08-24 01:54PM
08:10AM
07:10AM
(Associated Press Finance)
07:00AM
May-07-24 07:20AM
07:00AM
May-03-24 04:01PM
Apr-19-24 10:30AM
Apr-06-24 09:50AM
Apr-03-24 01:40PM
04:04PM
Loading…
Apr-02-24 04:04PM
(Investor's Business Daily) -34.95%
10:36AM
(Investor's Business Daily)
09:31AM
09:01AM
(Investor's Business Daily)
07:35AM
07:00AM
07:00AM
03:03AM
Mar-28-24 04:51PM
Mar-21-24 04:19PM
Mar-01-24 04:01PM
Feb-27-24 07:02PM
08:03AM
(Associated Press Finance)
07:30AM
Feb-19-24 04:08PM
Feb-13-24 06:05AM
Feb-12-24 08:30AM
Feb-01-24 06:30AM
Jan-31-24 12:28PM
Jan-17-24 12:04PM
Jan-11-24 04:38PM
Jan-04-24 08:00AM
(Investor's Business Daily)
Jan-02-24 06:30AM
Dec-29-23 12:00PM
09:55AM
Dec-13-23 09:55AM
Dec-06-23 12:31PM
Dec-01-23 04:00PM
Nov-28-23 10:37PM
04:01PM
Nov-27-23 09:55AM
Nov-20-23 04:26PM
(GlobeNewswire) +5.37%
-7.44%
Nov-17-23 03:41PM
Nov-16-23 05:41AM
05:20AM
Nov-13-23 07:20PM
(Barrons.com) -40.83%
+15.93%
04:03PM
(Investor's Business Daily)
02:28PM
12:17PM
(Associated Press Finance)
12:07PM
08:56AM
Nov-12-23 03:30PM
10:34AM
Nov-09-23 09:55AM
08:00AM
05:57AM
Nov-07-23 07:56AM
06:36AM
(Associated Press Finance)
06:30AM
Nov-06-23 08:02AM
(Investor's Business Daily)
Nov-01-23 07:06AM
05:40AM
Oct-31-23 07:09PM
04:04PM
(Investor's Business Daily)
06:01AM
05:00AM
Oct-30-23 03:46PM
08:30AM
Oct-25-23 01:45AM
Oct-23-23 07:38AM
06:30AM
Oct-10-23 09:45AM
Sep-27-23 07:49AM
Sep-26-23 06:30AM
Sep-21-23 04:05PM
Sep-18-23 06:30AM
Aug-31-23 10:30AM
Aug-11-23 09:10AM
Aug-10-23 07:50AM
06:40AM
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kathiresan Sekar Chief Executive Officer Jun 28 '24 Option Exercise 2.87 30,000 86,100 351,128 Jul 02 07:30 AM Ashe Andrew D. See Remarks May 14 '24 Buy 6.26 76,000 475,760 342,509 May 15 05:30 PM Nickerson Joan Chief Administrative Officer Apr 02 '24 Sale 8.24 1,514 12,475 8,659 Apr 03 05:00 PM Dorval Allison Chief Financial Officer Nov 29 '23 Sale 11.45 554 6,343 4,060 Dec 01 04:30 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
